Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom — CODAK  

Non-Small Cell Lung Cancer NSCLC Clinical Trial

Official title: CODAK: A Retrospective Observational Research Study to Describe the Characteristics and Real-world Clinical Outcomes of Patients With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer Receiving Durvalumab in the UK.

Status Completed

Clinical Trial Summary

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in the United Kingdom (the CODAK study). Physicians who have treated patients who have locally advanced, unresectable Stage III NSCLC with durvalumab will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients receiving durvalumab through the Early Access Programme (EAP) or post-reimbursement.

Clinical Trial Description

Primary Objectives

The primary study objectives, in patients with locally advanced, unresectable Stage III NSCLC treated with durvalumab as part of the UK EAP or non-EAP, are:

1. To describe clinical outcomes

2. To describe the patient demographic and clinical characteristics Secondary Objective

1. To describe treatment patterns of durvalumab ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer NSCLC

• NCT number: NCT04667312
• Study type: Observational
• Source: AstraZeneca
• Status: Completed
• Start date: June 24, 2021
• Completion date: September 28, 2022